ประวัติ
หน่วยวิชาโรคระบบทางเดินอาหาร รพ. สงขลานครินทร์? ก่อตั้งเมื่อปี พ.ศ. 2528 โดยมี รศ.นพ.บัญชา โอวาทฬารพร.  ผศ.นพ.อุทัย เก้าเอี้ยน และ อ.พญ. นภาพร จำรูญกุล และ รศ.นพ. ธีระ พิรัชวิสุทธิ์ เป็นหัวหน้าสาขาวิชาได้ช่วงเริ่มต้น หลังจากนั้นมีพัฒนาศักภาพของหน่วยวิชาและเป็นศูนย์อบรมแพทย์ประจำบ้านต่อยอดทางเดินอาหาร  โดยประกอบด้วยศูนย์ความเป็นเลิศ สถาบันโรคระบบทางเดินอาหารและตับ นันทนา – เกรียงไกร โชติวัฒนะพันธุ์  และหน่วยโรคระบบทางเดินอาหา เพื่อดูแลผู้ป่วยในโรคทางเดินอาหารที่ซับซ้อนและเป็นศูนย์ส่งต่อผู้ป่วยในภาคใต้ รวมถึงการจัดประชุมวิชาการประจำปี NKC annual meeting การศึกษาและพัฒนางานวิจัยในระดับประเทศและนานาชาติ

บุคลากร

ผศ.พญ.ณัยชญา จำรูญกุล Asst. Prof. Naichaya Chamroonkul M.D. หัวหน้าสาขาวิชา E-mail : naichaya@gmail.com โทรศัพท์ : 074-451479
รศ.นพ.ธีระ พิรัชวิสุทธิ์ Assoc. Prof. Teerha Piratvisuth M.D. E-mail : teerha.p@psu.ac.th เ	ผศ.พญ.พิมพ์ศิริ ศรีพงศ์พันธุ์ Asst. Prof. Pimsiri Sripongpun M.D. E-mail : pimsiri.s@psu.ac.th เลาฝึกอบรม Fellow สหรัฐอเมริกา
อ.นพ.สว่างพงษ์ จันดี Mr. Sawangpong Jandee M.D. E-mail : tekikung@gmail.com	อ.นพ.ภานุ เวชวิทยาขลัง Mr. Panu Wetwittayakhlang M.D. E-mail : wet.panu@gmail.com
อ.นพ.อภิชาติ แก้วเดช Mr. Apichat kaewdechM.D. E-mail : Apichatka@hotmail.com
อาจารย์พิเศษ
ผศ.นพ.อุทัย เก้าเอี้ยน Asst. Prof. Uthai KaoIan M.D. E-mail : uthai.k@psu.ac.th
สายสนับสนุน
น.ส. นารี อินทรศักดิ์ E-mail : inareet@gmail.com ตำแหน่ง : พยาบาล ชำนาญการ	นายชิต บุญโท E-mail : bochit@medicine.psu.ac.th ตำแหน่ง : ผู้ปฏิบัติงานพยาบาล ชำนาญงาน
นางอารมณ์ รัญดร E-mail : rarom@medicine.psu.ac.th ตำแหน่ง : พนักงานช่วยการพยาบาล ส1	นายธีรเดช พลันสังเกต E-mail : - ตำแหน่ง : พนักงานช่วยการพยาบาล ส1
นางสายพิณ ดาราวดี E-mail : dsaipin@medicine.psu.ac.th ตำแหน่ง : ผู้ปฏิบัติงานพยาบาล ปฏิบัติงาน	นายวรากร นิยม E-mail : warakorn.ni@hotmail.com ตำแหน่ง : พนักงานช่วยการพยาบาล ส1
น.ส.สุนิษา เพ็งทอง E-mail :su-psu@hotmail.com ตำแหน่ง : ผู้ปฏิบัติงานพยาบาล ปฏิบัติงาน

งานการเรียนการสอน (Teaching)

1. นักศึกษาแพทย์ชั้น preclinic และ clinic ได้แก่การสอนบรรยาย การสอน beside teaching การสอน case discussion  (Preclinic and Clinical medication students: Lecture, bedside teaching, case discussion in Gastroenterology and Hepatology)
2. แพทย์ประจำบ้านอายุรกรรม (Medical resident)
3. แพทย์ประจำบ้านต่อยอดและแพทย์ประจำบ้านต่อยอด advanced endoscopic ( GI fellow

and advanced endoscopic fellow)

1. นักศึกษาแพทย์และแพทย์ elective (Elective grogram for medical student and medical residents)

งานวิจัยที่ให้ความสนใจของหน่วยวิชา (field of interested study)

1. Hepatitis เช่น viral hepatitis  
2. Cirrhosis
3. Hepatocellular carcinoma
4. Endoscopy and EUS/ERCP
5. Gastrointestinal Motility disorder
6. Diseases of intestine

งานบริการทางการแพทย์ (Medical service)

1. Clinic เฉพาะทางโรคระบบทางเดินอาหารวันพุธ 13.00 – 16.30 น  (Special clinic for GI diseases)
2. การส่องกล้องทางเดินอาหารได้แก่ upper and lower GI endoscopy, EUS, ERCP, GI motility testing, Liver stiffness measurement, Liver biopsy  ( procedure e.g. upper and lower GI endoscopy, EUS, ERCP, GI motility testing, Liver stiffness measurement, Liver biopsy)
3. รับปรึกษาปัญหาผู้ป่วยโรคระบบทางเดินอาหารจากในแผนกและต่างแผนก รวมถึงเป็นศูนย์ refer ผู้ป่วยจากรพ.ในภาคใต้ (Consulataion for GI problem in Songanarind Hospital and referal center for patients with complicated GI problem)

งานบริการวิชาการ

• การประชุมวิชาการโรคทางเดินอาหารและตับระดับประเทศ? ( NKC Gastroenteroloy and Hepatology annual meeting)
• การจัดประชุม Live demonstration ทาง advanced endoscopy : EUS and ERCP (Liver demonstration work up for advanced endoscopy)
• เป็นวิทยากรในสมาคมวิชาชีพ ได้แก้ ราชวิทยาลัยอายุรแพทย์แห่งประเทศไทย สมาคมระบบทางเดินอาหาร สมาคมโรคตับ  และระดับนานาชาติ (Speaker in Gastroenterology and Hepatology of)
• ให้ความรู้แก่ประชาชนผ่านทางสื่อสิ่งพิมพ์ วิทยุ และการสัมภาษณ์สด

งานวิจัยของหน่วย

Our publish research

•  Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HLY, Pess?a MG, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS ONE. 2013;8(2):e54279.
• Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, et al. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018 Sep;48(5):547–55.
• McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013 Apr;57(4):1325–32.
• Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011 Jul;31 Suppl 2:61–80.
• Ferrante S, Elbasha EH, Piratvisuth T, Tanwandee T, Lerdlitruangsin S, Thongsawat S. Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand. Value Health. 2014 Nov;17(7):A677.
• Pawlotsky J-M, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang W-L, et al. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015 Oct;62(4):1013–23.
• Piratvisuth T, Dunne JB, Williams R, Tredger JM. Amlodipine improves hepatic hemodynamic and metabolic function in the isolated perfused rat liver after sequential cold and warm ischemia. Transplantation. 1995 Jul 15;60(1):23–8.
• Bansal MB, Chamroonkul N. Antifibrotics in liver disease: are we getting closer to clinical use? Hepatol Int. 2019 Jan;13(1):25–39.
• Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007 May;22(5):615–33.
• Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1–98.
• Liaw Y-F, Leung N, Kao J-H, Piratvisuth T, Gane E, Han K-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008 Sep;2(3):263–83.
• Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012 Jun;6(3):531–61.
• Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, et al. Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study. Antivir Ther (Lond). 2018;23(1):67–75.
• Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int. 2010 May;30(5):657–68.
• Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol. 2016 Feb 28;8(6):307–21.
• Prachayakul V, Aswakul P, Limsrivilai J, Anuchapreeda S, Bhanthumkomol P, Sripongpun P, et al. Benefit of “transparent soft-short-hood on the scope” for colonoscopy among experienced gastroenterologists and gastroenterologist trainee: a randomized, controlled trial. Surg Endosc. 2012 Apr;26(4):1041–6.
• Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, et al. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers. World J Gastroenterol. 2015 Jul 28;21(28):8660–9.
• Ahn SH, Chan HLY, Chen P-J, Cheng J, Goenka MK, Hou J, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010 Feb 20;4(1):386–95.
• Omata M, Dan Y, Daniele B, Plentz R, Rudolph KL, Manns M, et al. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S40-49.
• Netinatsunton N, Attasaranya S, Sottisuporn J, Witeerungrot T, Jongboonyanuparp T, Piratvisuth T, et al. Comparing cost-effectiveness between endoscopic ultrasound and endoscopic retrograde cholangiopancreatography in diagnosis of common bile duct stone in patients with predefined risks: A study from a developing country. Endosc Ultrasound. 2016 Jun;5(3):165–72.
• Marcellin P, Lau GKK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008 Apr;28(4):477–85.
• Lertpipopmetha K, Tubtawee T, Piratvisuth T, Chamroonkul N. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2016 01;17(11):4805–11.
• Lertpipopmetha K, Tubtawee T, Piratvisuth T, Chamroonkul N. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2016 01;17(11):4805–11.
• Piratvisuth T, Han GR, Pol S, Dong Y, Trylesinski A. Comprehensive review of telbivudine in pregnant women with chronic hepatitis B. World J Hepatol. 2016 Mar 28;8(9):452–60.
• Dan YY, Wong JB, Hamid SS, Han K-H, Jia JD, Liu C-J, et al. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int. 2014 Jul;8(3):382–94.
• Piratvisuth T, Tredger JM, Hayllar KA, Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation. Liver Transpl Surg. 1995 Sep;1(5):296–301.
• Bansal MB, Chamroonkul N. Correction to: Antifibrotics in liver disease: are we getting closer to clinical use? Hepatol Int. 2019 Jan;13(1):40–1.
• Lui YY-N, Tsoi KK-F, Wong VW-S, Kao J-H, Hou J-L, Teo E-K, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther (Lond). 2010;15(2):145–55.
• Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat. 2013 Apr;20(4):e115-123.
• Bonino F, Piratvisuth T, Brunetto MR, Liaw Y-F. Diagnostic markers of chronic hepatitis B infection and disease. Antivir Ther (Lond). 2010;15 Suppl 3:35–44.
• Lertpipopmetha K, Kongkamol C, Sripongpun P. Effect of Psyllium Fiber Supplementation on Diarrhea Incidence in Enteral Tube-Fed Patients: A Prospective, Randomized, and Controlled Trial. JPEN J Parenter Enteral Nutr. 2018 Dec 18;
• Piratvisuth T, Komolmit P, Chan HL, Tanwandee T, Sukeepaisarnjaroen W, Pessoa MG, et al. Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. Drugs Context. 2016;5:212294.
• Ovartlarnporn B, Piratvisuth T, Wacharasin R, Chongchitnant P, Maipang T, Petpichetchian C, et al. Endoscopic removal of stone in patients with retained common bile duct stone and T-tube after cholecystectomy. Is it justified? J Med Assoc Thai. 1992 Sep;75(9):524–8.
• Siripun A, Sripongpun P, Ovartlarnporn B. Endoscopic ultrasound-guided biliary intervention in patients with surgically altered anatomy. World J Gastrointest Endosc. 2015 Mar 16;7(3):283–9.
• Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012 Oct;6(4):809–10.
• Buster EHCJ, Hansen BE, Lau GKK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009 Dec;137(6):2002–9.
• Piratvisuth T, Siripaitoon P, Sriplug H, Ovartlarnporn B. Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. J Gastroenterol Hepatol. 1999 Feb;14(2):146–9.
• Lim SG, Phyo WW, Shah SR, Win KM, Hamid S, Piratvisuth T, et al. Findings from a large Asian chronic hepatitis C real-life study. J Viral Hepat. 2018 Dec;25(12):1533–42.
• Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology. 2011 Mar;53(3):1054–5; author reply 1055.
• Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, et al. Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. J Viral Hepat. 2019 Apr 10;
• Thanapirom K, Suksawatamnuay S, Sukeepaisarnjareon W, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, et al. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study. PLoS ONE. 2017;12(3):e0173263.
• Fried MW, Piratvisuth T, Lau GKK, Marcellin P, Chow W-C, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008 Feb;47(2):428–34.
• Praneenararat S, Chamroonkul N, Sripongpun P, Kanngurn S, Jarumanokul R, Piratvisuth T. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. BMC Gastroenterol. 2014 Dec 19;14:218.
• Chamroonkul N, Piratvisuth T. Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission. Paediatr Drugs. 2017 Jun;19(3):173–81.
• Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011 Nov;55(5):1121–31.
• Piratvisuth T, Marcellin P, Popescu M, Kapprell H-P, Rothe V, Lu Z-M. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013 Jun;7(2):429–36.
• Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009 Apr;49(4):1141–50.
• Sooklim K, Sriplung H, Piratvisuth T. Histologic subtypes of hepatocellular carcinoma in the southern Thai population. Asian Pac J Cancer Prev. 2003 Dec;4(4):302–6.
• Chamroonkul N, Bansal MB. HIV and the liver. Nat Rev Gastroenterol Hepatol. 2019 Jan;16(1):1–2.
• Netinatsunton N, Sottisuporn J, Attasaranya S, Witeerungrot T, Chamroonkul N, Jongboonyanuparp T, et al. i-Scan detection of minimal change esophagitis in dyspeptic patients with or without Gastroesophageal Reflux disease. BMC Gastroenterol. 2016 Jan 14;16:4.
• Tangpradabkiet W, Praneenararat S, Chamroonkul N, Witeerungrot T, Piratvisuth T. Influence of meal intake on liver stiffness in patients with chronic hepatitis B and C. J Med Assoc Thai. 2014 Oct;97(10):1033–9.
• Tangpradabkiet W, Praneenararat S, Chamroonkul N, Witeerungrot T, Piratvisuth T. Influence of meal intake on liver stiffness in patients with chronic hepatitis B and C. J Med Assoc Thai. 2014 Oct;97(10):1033–9.
• Thampanitchawong P, Piratvisuth T. Liver biopsy:complications and risk factors. World J Gastroenterol. 1999 Aug;5(4):301–4.
• Lim SG, Aghemo A, Chen P-J, Dan YY, Gane E, Gani R, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2(1):52–62.
• Wei L, Wedemeyer H, Liaw Y-F, Chan HL-Y, Piratvisuth T, Marcellin P, et al. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS ONE. 2018;13(7):e0199198.
• Piratvisuth T. Optimal management of HBV infection during pregnancy. Liver Int. 2013 Feb;33 Suppl 1:188–94.
• Sonneveld MJ, Brouwer WP, Chan HL-Y, Piratvisuth T, Jia J-D, Zeuzem S, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol. 2019 Apr 8;
• Pavlovic V, Yang L, Chan HL-Y, Hou J, Janssen HL, Kao J-H, et al. Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. Antivir Ther (Lond). 2019;24(2):133–40.
• Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004 Sep 16;351(12):1206–17.
• Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2682–95.
• Cooksley WGE, Piratvisuth T, Lee S-D, Mahachai V, Chao Y-C, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305.
• You J, Zhuang L, Zhang Y-F, Chen H-Y, Sriplung H, Geater A, et al. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. World J Gastroenterol. 2009 Jul 21;15(27):3382–93.
• Kaewdech A, Sripongpun P. Phlegmonous Proctitis: A Rare Entity of the Presentation of Proctitis. Case Rep Gastroenterol. 2018 Aug;12(2):254–9.
• Mohamed R, Desmond P, Suh D-J, Amarapurkar D, Gane E, Guangbi Y, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol. 2004 Sep;19(9):958–69.
• Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007 May;56(5):699–705.
• Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, et al. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct;42(7):829–44.
• Chan HLY, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na?ve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012 Oct;19(10):732–43.
• Pianko S, Zeuzem S, Chuang W-L, Foster GR, Sarin SK, Flisiak R, et al. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. J Viral Hepat. 2012 Sep;19(9):623–34.
• Colvin RA, Tanwandee T, Piratvisuth T, Thongsawat S, Hui AJ, Zhang H, et al. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2015 Jan;30(1):184–91.
• Lim SG, Amarapurkar DN, Chan HL-Y, Crawford DH, Gane EJ, Han K-H, et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int. 2015 Jan;9(1):43–51.
• Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007 Aug;5(8):890–7.
• Thongsawat S, Piratvisuth T, Pramoolsinsap C, Chutaputti A, Tanwandee T, Thongsuk D. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Value Health Reg Issues. 2014 May;3:12–8.
• Sonneveld MJ, Hansen BE, Piratvisuth T, Jia J-D, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013 Sep;58(3):872–80.
• Chuang W-L, Jia J, Chan HLY, Han K-H, Tanwandee T, Tan D, et al. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Aliment Pharmacol Ther. 2018 May;47(9):1306–16.
• Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol. 2000 Jun;6(3):339–43.
• Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int. 2008 Jun;2(2):140–6.
• Tanwandee T, Piratvisuth T, Phornphutkul K, Mairiang P, Permpikul P, Poovorawan Y. Risk factors of hepatitis C virus infection in blood donors in Thailand: a multicenter case-control study. J Med Assoc Thai. 2006 Nov;89 Suppl 5:S79-83.
• Bannangkoon K, Hongsakul K, Tubtawee T, Piratvisuth T. Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization. Clin Mol Hepatol. 2019;25(1):74–85.
• Liaw Y-F, Jia J-D, Chan HLY, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011 Nov;54(5):1591–9.
• Sripongpun P, Attasaranya S, Chamroonkul N, Sookpaisal T, Khow-Ean U, Siripun A, et al. Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents. J Gastrointest Cancer. 2018 Jun;49(2):138–43.
• Sripongpun P, Attasaranya S, Chamroonkul N, Sookpaisal T, Khow-Ean U, Siripun A, et al. Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents. J Gastrointest Cancer. 2018 Jun;49(2):138–43.
• Sripongpun P, Attasaranya S, Chamroonkul N, Sookpaisal T, Khow-Ean U, Siripun A, et al. Simple Clinical Score to Predict 24-Week Survival Times in Patients with Inoperable Malignant Distal Biliary Obstruction as a Tool for Selecting Palliative Metallic or Plastic Stents. J Gastrointest Cancer. 2018 Jun;49(2):138–43.
• Wei L, Lim SG, Xie Q, V?n KN, Piratvisuth T, Huang Y, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127–34.
• Marcellin P, Bonino F, Lau GKK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4.
• Piratvisuth T, Lau G, Chao Y-C, Jin R, Chutaputti A, Zhang Q-B, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008 Mar;2(1):102–10.
• Ahn S-H, Kweon Y-O, Paik S-W, Sohn J-H, Lee K-S, Kim DJ, et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2012 Oct;6(4):696–706.
• Netinatsunton N, Attasaranya S, Ovartlarnporn B, Sangnil S, Boonviriya S, Piratvisuth T. The value of Carlsson-dent questionnaire in diagnosis of gastroesophageal reflux disease in area with low prevalence of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2011 Apr;17(2):164–8.
• Sung JJY, Amarapurkar D, Chan HLY, Cheng J, Kao J-H, Han K-H, et al. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? Antivir Ther (Lond). 2010;15(4):607–16.
• Dunne JB, Piratvisuth T, Williams R, Tredger JM. Treatment of experimental ischemia/reperfusion injury with S-adenyosylmethionine: evidence that donor pretreatment complements other regimens. Transplantation. 1997 Feb 27;63(4):500–6.
• Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol. 2016 Nov;31(11):1874–81.